Testing a new cancer treatment in adults with advanced tumors

Plain-English translation of NCT05969041 on ClinicalTrials.gov ↗ · Source last updated January 2024 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a Phase 1 trial testing MT-302, a new medication designed to treat advanced epithelial cancers—cancers that have spread or are no longer responding to standard treatments. Researchers want to find the safest and most effective dose of this medication by gradually increasing doses in different groups of patients. The trial will also measure how the medication moves through your body and how well it works against your cancer.

Standard cancer treatments don't work for everyone, and some patients' cancers become resistant to existing therapies. This trial exists to explore whether this new treatment can help patients whose cancers have stopped responding to conventional options.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with advanced or metastatic epithelial cancer (such as breast, ovarian, pancreatic, lung, colorectal, or other specified types) that has progressed despite standard treatment
you have measurable disease that can be tracked on imaging scans
you are generally healthy enough to tolerate treatment (Eastern Cooperative Oncology Group performance status of 0 or 1)
you have a life expectancy of more than 12 weeks
you are willing to attend clinic visits, receive intravenous infusions, and possibly undergo tumor biopsies

You likely don't qualify if…

you have active cancer spread to the brain or spinal cord that has not been treated
you are pregnant, nursing, or unwilling to use effective contraception
you have had major surgery within the past 28 days
you have a fever or active infection in the 7 days before starting treatment
you have active HIV, hepatitis B, or hepatitis C

What participation looks like

You will receive the medication through an intravenous infusion (IV) during clinic visits. The dosing schedule varies by group: some participants receive infusions every 2 weeks for 3 doses, then once monthly for 3 more doses, while others receive weekly infusions for 3 weeks followed by monthly doses. You'll have frequent doctor visits, blood tests, heart function tests (echocardiogram and EKG), and imaging scans to monitor your safety and how well the treatment is working. The entire study lasts several months.

AI-generated summary from trial data · Jun 13, 2026 · Not medical advice

Trial locations(6 sites)

Australia

St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales

Scientia Clinical Research Ltd, Randwick, New South Wales

Westmead Hospital, Westmead, New South Wales

Souther Oncology Clinical Research Unit (SOCRU), Bedford Park, South Australia

Cabrini Health, Malvern, Victoria